Teethaisong, Y, Evans, K, Nakouti, I, Tiamyom, K, Ketudat-Cairns, JR, Hobbs, G and Eumkeb, G

The performance of a resazurin chromogenic agar plate with a combined disc method for rapid screening of extended-spectrum-β-lactamases, AmpC β-lactamases and co-β-lactamases in Enterobacteriaceae.

http://researchonline.ljmu.ac.uk/6807/

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)


LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk
The performance of a resazurin chromogenic agar plate with a combined disc method for rapid screening of extended-spectrum-β-lactamases, AmpC β-lactamases and co-β-lactamases in Enterobacteriaceae.

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Microbiology and Immunology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>MAI-2017-036</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Article</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>15-Feb-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Teethaisong, Yothin; Suranaree University of Technology, School of Preclinical, Institute of Science  
Evans, Katie; Liverpool John Moores University Faculty of Science, School of Pharmacy and Biomolecular Sciences  
Nakouti, Ismini; Liverpool John Moores University School of Pharmacy and Biomolecular Sciences  
Tiamyom, Kanokwan; Suranaree University of Technology, School of Preclinical, Institute of Science  
R. Ketudat-Cairns, James; Suranaree University of Technology, School of Biochemistry, Institute of Science  
Hobbs, Glyn; Liverpool John Moores University School of Pharmacy and Biomolecular Sciences  
Eumkeb, Griangsak; Suranaree University of Technology, School of Preclinical, Institute of Science |
| Keywords: | Resazurin chromogenic agar, cefpodoxime combined disc, phenotypic test, β-lactamases, Enterobacteriaceae |
The performance of a resazurin chromogenic agar plate with a combined disc method for rapid screening of extended-spectrum-β-lactamases, AmpC β-lactamases and co-β-lactamases in Enterobacteriaceae.

Running title: Screening of ESBL and AmpC β-lactamases

Authors:

Yothin Teethaisong,1,2 Katie Evans,1 Ismini Nakouti,1 Kanokwan Tiamyom,1 James R. Ketudat-Cairns,3 Glyn Hobbs1, Griangsk Eumkeb2*

Affiliations:

1 School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, United Kingdom.
2 School of Preclin, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.
3 School of Biochemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand.

Corresponding author:

* Dr. Griangsk Eumkeb
Email: griang2504@gmail.com, Tel.: +66-44-224260.
ABSTRACT

A resazurin chromogenic agar (RCA) along with combined disc method has been developed as a promising method for rapid screening of extended-spectrum-β-lactamase (ESBL), AmpC β-lactamase, and co-production of ESBL and AmpC. Cefpodoxime (CPD) discs supplemented with and without clavulanic acid (CA), cloxacillin (CX), or CA+CX were evaluated against 86-molecularly confirmed β-lactamase-producing Enterobacteriaceae, including 15 ESBLs, 32 AmpCs, 9 co-producers of ESBL and AmpC, and 30 carbapenemase producers. The CA and CX synergy test successfully detected all ESBL producers (100% sensitivity and 98.6% specificity) and all AmpC producers (100% sensitivity and 96.36% specificity). This assay also exhibited a good performance in the screening for the co-existence of ESBL and AmpC (88.89% sensitivity and 100% specificity). The RCA assay is a simple and inexpensive method that allows observation of results within 7 h. It can be applicable in any microbiological laboratory, especially in the endemic areas of ESBL, AmpC, or co-β-lactamase-producing Enterobacteriaceae.

KEYWORDS: Resazurin chromogenic agar, cefpodoxime combined disc, phenotypic test, β-lactamases, Enterobacteriaceae.
1. INTRODUCTION

An increasing number of antibiotic-resistant opportunistic pathogens have globally been documented in recent years resulting in decreasing effective antibiotic availability. Not surprisingly, these problems have created a treatment challenge and pose a serious health risk affecting both hospitalized patients and health care providers (1-3). β-Lactamase-associated resistance is a predominant mechanism of resistance to β-lactam antibiotics in Enterobacteriaceae. The dissemination of resistance in these bacteria is frequently facilitated by transferring mobile genetic elements among bacteria (4).

Currently, infections caused by multidrug-resistant (MDR) Gram-negative bacteria, in particular ESBL-producing Enterobacteriaceae, are among one of the most serious human health concerns (5). $\text{bla}_{\text{TEM}}, \text{bla}_{\text{SHV}},$ and $\text{bla}_{\text{CTX-M}}$ genes are the most common ESBL genotypes among Enterobacteriaceae. ESBL-producing isolates characteristically hydrolyze cefotaxime, ceftazidime, cefepime and/or monobactam aztreonam, rendering these antibiotics inactive (6-8). ESBLs are inhibited by β-lactamase inhibitors, namely clavulanate, sulbactam and tazobactam. False-negative ESBL test results using combination disc tests may result from high-level expression of AmpC β-lactamases, which masks the presence of ESBLs. Using CA and CX together allows detection of co-production of ESBL and AmpC (9). In addition, AmpC β-lactamase (AmpC)-producers and co-producers of AmpC and ESBL have also been reported to be resistant to third-generation cephalosporins, cephemycins or β-lactam/β-lactamase inhibitor combinations (10). Infections caused by AmpC-producing organisms are typically associated with resistance to multiple antibiotics, such as penicillins, oxyimino-7α-methoxycephalosporins and monobactams (11, 12). In general, AmpC type enzymes are poorly inhibited by β-lactamase inhibitors, especially clavulanic acid. Phenotypic
AmpC confirmation tests are generally based on inhibition of AmpC by either cloxacillin or boronic acid derivatives. Boronic acid also inhibits class A carbapenemases (13), justifying the use of cloxacillin in the present study. Moreover, co-expression of ESBL and AmpC β-lactamases results in decreased susceptibility to aztreonam and β-lactam/lactamase inhibitors than those with either ESBL or AmpC β-lactamase alone (14). This makes the selection of an effective antibiotic difficult for the treatment of infections caused by these recalcitrant bacteria.

A simple, rapid and inexpensive method for screening and discrimination between these enzymes at a phenotypic level could guide clinicians to prescribe an appropriate chemotherapy. The combined disc method has been used extensively because it is relatively easy to prepare and perform. However, this test requires at least 18 h or overnight to obtain the results. A resazurin reduction assay, a colorimetric method, is based upon the ability of active cells to reduce a blue colored resazurin to a pink colored resorufin (15). A colorimetric (resazurin containing) disc susceptibility method exhibited excellent reproducibility (16) and high sensitivity and specificity in detection and differentiation of carbapenemase-producing Enterobacteriaceae (17). Cefpodoxime (CPD) is an attractive indicator cephalosporin for detection of ESBL production and may be used for screening according to EUCAST guidelines. There are several diagnostic methods that have been proposed for phenotypic confirmation of ESBL and AmpC β-lactamases, including the Etest, combined disc method e.g. MAST D68C test, double disc synergy test, automated broth microdilution test. The time to result for these methods usually takes at least 18 h (9, 18, 19). Hence, the present study has investigated a resazurin chromogenic agar (RCA) method together with cefpodoxime (CPD) discs alone or supplemented with clavulanic acid (CA), cloxacillin (CX), and
both CA and CX to screen for and discriminate between ESBL, AmpC, and coexistence of ESBL-AmpC among Enterobacteriaceae.

2. MATERIALS AND METHODS

2.1 Bacterial isolates

The present study employed a total of 86 β-lactamase-producing Enterobacteriaceae isolates to evaluate the performance of the RCA assay in rapid screening and discrimination of ESBL, AmpC, and co-producers of ESBL and AmpC. The organisms used in the present study are summarized in Table 1 (17, 20). The molecular types included 15 Ambler class A ESBL producers (4 CTX-M-types, 3 SHV-types, 3 TEM-types, 1 CTX-M+SHV-type, 3 SHV+TEM-types, and 1 CTX-M+SHV+TEM-type), 32 Ambler class C AmpC producers (6 DHA family, 7 CIT family, 2 MOX family, 11 EBC family, and 6 FOX family) and 9 co-producers of ESBL and AmpC (1 TEM+ACT-type, 4 CTX-M+ACT-types, 1 TEM+SHV+ACT-type, 1 TEM+CTX-M+ACT-type, 1 SHV+ACT type, and 1 SHV+CTX-M-ACT-type). Thirty carbapenemase-producing isolates (8 KPC, 11 MBL, and 11 OXA-48 producers) were also included to validate the performance of the RCA plate assay. A reference strain E. coli ATCC 25922 was used as a negative β-lactamase control strain. The following β-lactamase-producing isolates obtained from the American Type Culture Collection (ATCC) and National Collection of Type Cultures (NCTC) were used as controls; E. cloacae ATCC BAA-1143 (bla_{ACT,32}), E. coli NCTC 13352 (bla_{TEM,10}) and E. coli NCTC 13353 (bla_{CTX-M,15}).
2.2 Resazurin chromogenic agar (RCA) plate and disc preparations

RCA plates were prepared according to previous studies (16, 17). For the preparation of the antibiotic- or β-lactamase inhibitor-containing discs, 10 µg of CPD discs (MAST Group, UK) were supplemented with 10 µl of 1 mg/mL CA (Sigma-Aldrich, UK), 10 µl of CX (Sigma-Aldrich, UK) at a concentration of 50 mg/mL, or impregnated with both CA and CX. Meropenem (MER) discs (10 µg) were prepared by adding 10 µl of MER (Sigma-Aldrich, UK) at a concentration of 1 mg/mL to blank discs (6.5 mm diameter, MAST Group, UK). Prior to performing disc diffusion susceptibility testing, the discs were air-dried in a biosafety cabinet for 1 h.

2.3 Disc diffusion susceptibility testing

The algorithm for phenotypic screening of ESBL, AmpC, and co-producers of ESBL and AmpC is illustrated in Figure 1. The experimental procedure for disc diffusion susceptibility testing was carried out according to the Clinical Laboratory Standards Institute (CLSI) guidelines (21). Briefly, a sterile swab soaked in a 0.5 McFarland standard of test organism was spread entirely on the surface of the RCA plate. Discs containing CPD alone, CPD plus CA, CPD plus CX, CPD plus CA and CX, and MER alone were placed equidistantly on the RCA’s surface. The MER disc was used to screen for carbapenem resistance including carbapenemase production. The inhibition zone diameters were scrupulously measured and interpreted following incubation at 37 °C for 7 h by observing a change in the medium from the original blue (resazurin) colour to pink (resorufin). The interpretation criteria in screening and differentiation of ESBL, AmpC, and co-β-lactamases were based upon a previous report as presented in Table 2 (19). An increase in zone diameter (≥5 mm) of CPD supplemented with β-
lactamase inhibitor compared with CPD alone was considered as synergistic activity. To interpret the results, CA synergy was considered as a positive result for ESBL, while CX synergy and CA plus CX synergy were noted as positive results for AmpC and co-production of ESBL and AmpC, respectively. A zone diameter of MER < 25 mm was used at a cut-off point to screen for the presence of carbapenemases. Sensitivity and specificity of the RCA assay with a combined disc method were calculated by comparing the results with molecular types from PCR and sequencing data. A box-and-whisker plot was analyzed using SPSS statistical analysis program version 18 (SPSS Inc, USA) to elucidate the distribution of zone diameters of discs against different β-lactamase producers.

3. RESULTS

Using the RCA assay along with a combined disc method for phenotypic confirmation of ESBL, AmpC, and co-expression of ESBL plus AmpC clearly showed the inhibition zone diameters within 7 h (Figure 2). Figure 3 illustrates the distribution of the zone diameters of CPD impregnated with and without CA, CX, or CA plus CX, and MER alone against ESBL, AmpC, co-existence of ESBL and AmpC, and carbapenemase-producing Enterobacteriaceae. For screening of ESBL-producing isolates, the median zone diameter of CPD alone was 6.5 mm (range = 6.5-16 mm) and diameters of CPD supplemented with CA, CX, or CA plus CX were 22 mm (range = 19-25 mm), 6.5 mm (range = 6.5-17 mm), and 23 mm (range = 21-25 mm), respectively. MER discs exhibited potential activity in inhibition of ESBL producers with a median zone diameter 25 mm (range = 23-27 mm) (Figure 3A). A substantial increase in zone diameters of CA-containing discs compared with the discs without CA was only
observed in ESBL-producing isolates. The mean zone increase of CPD plus CA compared with CPD alone was 14.60 mm (range = 5-17.50 mm). No marked increase in zone diameter was observed in AmpC producers (mean = 0.48 mm and range = 1.5-3.5 mm), co-producers of ESBL and AmpC (mean = 2.72 mm and range 1.5-8.5 mm), as well as carbapenemase-producing isolates (mean = 0.37 mm and range = 0-5.5 mm). The RCA assay with combined disc method successfully detected all test ESBL producers with 100% sensitivity and 98.6 % specificity (Table 2). A false-positive result was observed in an OXA-48-producing E. coli.

In AmpC producers, an increase in median zone diameters was seen in CX-containing discs. CPD plus CX and CPD plus CX plus CA had equally a median zone diameter of 20 mm and a range 12-26 mm. The median zone diameter of CPD against these isolates was 7.25 mm (range = 6.5-20 mm) which was similar to CPD plus CA (median = 8 mm and range =6.25-21 mm). MER discs inhibited the growth of AmpC-producing isolates at a median zone diameter of 25 mm and range 23-28 mm (Figure 3B). The mean difference of zone diameter of CPD plus CX versus CPD alone was 10.09 mm (range = 5.50 -16.50 mm) against AmpC producers, whilst no dramatic difference in mean zone increase was observed in ESBL producers (mean =0.33 mm and range = 0-2 mm), co-producers of ESBL and AmpC (mean = 4.33 mm and range = 1-7.5 mm), or carbapenemase producers (mean = 0.88 mm and range = 0-9.5 mm). The RCA assay demonstrated an excellence performance in the screening of AmpC-producing strains by detecting all test AmpC producers (100 % sensitivity), but there were two false-positives in KPC-3-producing K. pneumoniae and OXA-48-producing E. coli (96.36 % specificity; Table 2).

For screening of ESBL and AmpC-co-producing Enterobacteriaceae, CPD discs alone
exhibited a median zone diameter of 9 mm (range = 6.5-22 mm). CPD plus CA (median = 15 mm and range = 6.5-22 mm) and CPD plus CX (median = 14 mm and range = 10-27 mm) showed a slight increase in median zone diameter compared with CPD alone.

CPD plus CA plus CX demonstrated excellent activity in inhibiting the growth of ESBL and AmpC co-producers. The median zone was significantly increased (median = 24 mm and range = 21-27 mm) in comparison with those of CPD alone, CPD plus CA, and CPD plus CX. The median zone diameter and zone range of MER against these isolates were 25 mm and 23-26 mm, respectively (Figure 3C). The mean difference in zone diameter of CPD plus CA and CX versus CPD plus CA, or versus CPD plus CX was also calculated. The mean zone increase of CPD plus CA and CX versus CPD plus CA was 11.61 mm (range=5-19.5 mm). A similar result was observed in CPD plus CA and CX versus CPD plus CX. The sensitivity and specificity of the RCA assay with the combined disc method were 88.89% and 100%, respectively (Table 2). The assay failed to detect ESBL activity in a SHV plus ACT-producing *E. aerogenes*. Furthermore, in carbapenemase-producing isolates, the median zone diameters of CPD with and without CA, CX, or CA and CX were not markedly different, while the ranges did vary. The MER disc alone had a median zone diameter of 17 mm and range 6.5-25 mm. A reference strain *E. coli* ATCC 25922 was inhibited by a CPD disc alone with zone diameter 25 mm which was in the susceptible range according to the CLSI breakpoint (≥21 mm) (22). The findings of this study demonstrated that the RCA assay with CPD combination discs showed an excellent performance in screening of and differentiation between ESBL, AmpC, and co-production of ESBL and AmpC in Enterobacteriaceae.
4. DISCUSSION

Resistance to β-lactams, the most potent bactericidal antibiotics commonly used for the
treatment of bacterial infections, has been continuously documented throughout the
globe. β-Lactamase-mediated resistance is a major mechanism that can potentially
render β-lactams inactive by hydrolytically cleaving the amide bond of the β-lactam
ring (23). To guide clinicians to prescribe antibiotic therapy appropriately, development
of quick phenotypic methods is necessary. The detection of the presence of β-lactamase
enzymes in Gram-negative bacteria at the phenotypic level is useful because it is not
costly compared with genotypic tests (PCR and sequencing). Also, a phenotypic method
does not require skilled and experienced technicians (24). The principle of the
phenotypic test is fundamentally based upon a synergistic effect between antibiotics and
β-lactamase inhibitors (25). Several phenotypic tests for the detection of β-lactamase
enzymes in Gram-negative bacteria have currently been proposed including disc
diffusion assays and broth microdilution methods (9, 19, 26, 27). The time to interpret
these results usually takes 18 h or overnight incubation (28, 29). In the present study,
we propose the rapid screening method using RCA assay along with CPD combined
disc method to detect the presence of and discriminate between β-lactamases within 7
h.

CA synergy test using the RCA assay with CPD combined discs to confirm the presence
of ESBL production in Enterobacteriaceae was capable of detecting all test ESBL-
producing isolates. There was only one false-positive found in an OXA-48-producing
isolate. This finding agrees with a previous report published by Derbyshire and
colleagues (26). They found that a CA synergy test using CPD was able to detect all 117
ESBL producers indicated by a ≥ 5 mm increase in zone diameter of CPD plus CA in
comparison with CPD alone. This synergy test could not detect ESBLs in the co-

presence with AmpCs. Similarly, CPD exhibited excellent performance in the screening

of ESBL in *K. pneumoniae* and *E. coli*, but poor sensitivity for *K. oxytoca* (30, 31). The

presence of ESBLs may also be masked by carbapenemases such as MBLs or KPCs

(32). Furthermore, not all OXA-48-variants exhibit significant carbapenemase activity,

some OXA-48 variants such as OXA-163 and OXA-405 have been reported to be

resistant to either carbapenem antibiotics or to extended-spectrum cephalosporins.

These two variants were significantly inhibited by CA (33, 34). We speculate that a

OXA-48-like-producing isolate used in the present study might have low

carbapenemase activity as indicated by relatively large zone diameter for MER (22 mm)

and might also co-produce ESBL.

For screening of AmpC-producing isolates using CX synergy test, the assay was able to

detect all AmpC producers and two false positive results (100% Sensitivity and 96.36%

specificity). This result is consistent with many previous works reporting a good

performance of CPD and CX synergy test in detection of these enzymes. In one such

study MAST® D68C successfully detected almost all AmpC producers whilst a few

false-positive results were also reported (96.7 % sensitivity and 96.9% specificity). The

test could not detect the low production of AmpC β-lactamases in AmpC-producing

isolates (19). A similar result was reported by Ingram and colleagues, they found that

MAST® D68C exhibited a sensitivity and specificity above 90% in detection of the

presence of AmpC β-lactamase in Enterobacteriaceae. In agreement with a previous

study, MAST-4 disc demonstrated good sensitivity (92%) and specificity (86.7%) in the

detection of AmpC-producing nosocomial *Klebsiella* isolates (35). Combined activity of

ESBL and AmpC in the same strain can result in phenotypic detection failure (36). Co-
production with AmpC β-lactamases can mask ESBL production with CLSI confirmatory tests leading to false-negative results (37). Therefore, adding two or more specific β-lactamase inhibitors could exclude different types of β-lactamase in the same strain. In the present study, we used CA plus CX synergy test to discriminate co-producers of ESBL and AmpC. The assay was able to detect 8 co-producers of ESBL and AmpC. Only AmpC was detected in one co-producer of ESBL and AmpC. This false-negative isolate was susceptible to CPD according to the CLSI breakpoint (Clinical Laboratory Standards Institute, 2014). The finding from this study is similar to the result from a previously mentioned study where MAST® D68C was reported to successfully detect all 8 ESBL and AmpC-co-producing isolates (19).

To screen carbapenemase-producing isolates, it has been recommended to use a cut-off point lower than 25 mm for MER disc because the zone diameter of MER in some OXA-48 like-producing bacteria is still in the susceptible range (≥ 23 mm) (38, 39). The current study found that MER zone diameters against ESBL, AmpC, and Co-ESBL and AmpC ranged from 23-28 mm, whilst in carbapenemase-producing isolates zone diameters ranged from 6.5 – 25 mm. Only one OXA-48 producing isolate had a zone diameter of 25 mm. Thus, the isolates showing zone diameters < 25mm for 10 μg MER disc should be further investigated to detect the distinct type of carbapenemase (metallo-β-lactamas, Klebsiella pneumoniae carbapenemases, and OXA-48 like carbapenemases) or AmpC plus porin loss.

To summarize, the combined disc test is commonly used in many microbiological laboratories, because it is very simple. The conventional method takes at least 18 h to observe the inhibition zone diameter. In the present study, we support the use of the RCA assay to improve a time to result for the disc diffusion susceptibility test. The
result from RCA assay can be observed within 7 h. It also demonstrates excellent sensitivity and specificity for differentiation of ESBL, AmpC, and co-ESBL and AmpC-producing Enterobacteriaceae. The RCA assay could be applicable to commercially available discs, including MAST discs (Mast Group, UK) and it can also be applied in CLSI ESBL confirmatory tests and any disc diffusion method. However, a larger sample size of clinical isolates is still required to further validate and establish the robustness of this assay. A rapid phenotypic method that can detect and differentiate the different types of β-lactamase would improve the effectiveness of antibiotic administration and would also help to control the dissemination of the infection caused by these refractory bacteria.

ACKNOWLEDGEMENT

This work was supported by Thailand Research Fund through The Royal Golden Jubilee Ph.D. Program (Grant No. PHD/0125/2554) and Newton Fund via British Council Thailand. We are very grateful to Suranaree University of Technology and Liverpool John Moores University for the facilities to perform this project.

DISCLOSURE

The authors have no conflict of interest to declare.
REFERENCES


20. Teethaisong, Y., Eumkeb, G., Chumnarinsilpa, S., Autarkool, N., Hobson, J.,
Nakouti, I., Hobbs, G., Evans, K. (2016) Phenotypic detection of AmpC beta-
lactamases, extended-spectrum beta-lactamases and metallo-beta-lactamases in
Enterobacteriaceae using a resazurin microtitre assay with inhibitor-based

antimicrobial disk susceptibility tests; approved standard CLSI document M02-
A10, 10 edn. Wayne, PA, USA.

antimicrobial susceptibility testing; Twenty-fourth informational supplement
CLSI document M100-S24, 10 edn. CLSI, Wayne, PA, USA.


(2009) A simple disc diffusion method for detecting AmpC and extended-


**FIGURE LEGENDS**

**Figure 1.** The algorithm for confirmation of and differentiation between ESBL, AmpC, and co-production of ESBL and AmpC in Enterobacteriaceae. CA= clavulanic acid (10 µg); CX = cloxacillin (500 µg).

**Figure 2.** Phenotypic results from RCA plate assay with a combined disc method at 7 h. A = cefpodoxime (10 µg); B = cefpodoxime (10 µg) + clavulanic acid (10 µg); C = cefpodoxime (10 µg) + cloxacillin (500 µg); D = cefpodoxime (10 µg) + clavulanic acid (10 µg) + cloxacillin (500 µg); E = meropenem (10 µg).

**Figure 3.** Distribution of zone diameters of cefpodoxime (CPD) alone, CPD with clavulanic acid, CPD with cloxacillin, CPD with both clavulanic acid and cloxacillin and meropenem alone. A = ESBL producers (n=15); B = AmpC producers (n=32); C= co-producers AmpC and ESBL (n=9); D = carapenemase producers (n=30). CPD= cefpodoxime (10 µg); CA= clavulanic acid (10 µg); CX= cloxacillin (500 µg); MER = meropenem (10 µg). * = mild outlier; * = extreme outlier.
454  Tables

455  

456  Table 1. Summary of ESBL, AmpC, ESBL+AmpC and carbapenemase-producing isolates used in the present study. Abbreviation for Organism; EC = E. coli, KP = K. pneumoniae, EA = E. aerogenes, ECL = E. cloacae, MM = M. morganii, CF = C. freundii, KOX = K. oxytoca, KOZ = K. ozaenae. Abbreviation for β-lactamase; ESBL = extended-spectrum-β-lactamase, KPC = Klebsiella pneumoniae carbapenemase, MBL = metallo-β-lactamase.

457  

458  Table 2. Interpretation criteria, sensitivity, and specificity of a combined disc synergy method along with RCA assay for rapid screening of ESBL, AmpC, and co-producers of ESBL and AmpC among Enterobacteriaceae. CPD = cefpodoxime (10 µg); CA = clavulanic acid (10 µg); CX = cloxacillin (500 µg).
Table 1. Summary of ESBL, AmpC, ESBL+AmpC and carbapenemase-producing isolates used in the present study.

<table>
<thead>
<tr>
<th>Group of β-lactamases</th>
<th>EC</th>
<th>KP</th>
<th>EA</th>
<th>ECL</th>
<th>MM</th>
<th>CF</th>
<th>KOX</th>
<th>KOZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambler class A ESBL (n =15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTX-M family (n=4)</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHV family (n=3)</td>
<td></td>
<td>2</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEM family (n=3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTX-M + SHV (n=1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHV + TEM (n=3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTX-M + SHV+TEM (n=1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ambler class C AmpC (n =32)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA family (n=6)</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CIT family (n=7)</td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOX family (n=2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBC family (n=11)</td>
<td>1</td>
<td>3</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOX family (n=6)</td>
<td>2</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class A + Class C (n=9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEM+ACT (n=1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTX-M + ACT (n=4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEM+SHV+ACT (n=1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEM+CTX-M+ACT (n=1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHV+ACT (n=1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHV+CTX-M+ACT (n=1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbapenemase producers (n=30)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>class A KPC (n=8)</td>
<td>2</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>class A MBL (n=11)</td>
<td>1</td>
<td>7</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Ambler class D OXA-48 (n=11)</td>
<td>4</td>
<td>5</td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total (number of isolates) | 25 | 28 | 12 | 13 | 2  | 4  | 1   | 1   |

Table 2. Interpretation criteria, sensitivity, and specificity of a combined disc synergy method along with RCA assay for rapid screening of ESBL, AmpC, and co-producers of ESBL and AmpC among Enterobacteriaceae.

<table>
<thead>
<tr>
<th>Synergy test</th>
<th>Definition of the test</th>
<th>ESBL</th>
<th>AmpC</th>
<th>ESBL+ AmpC</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA synergy test</td>
<td>CPD+CA vs CPD ≥ 5 mm and CPD+CA+CX vs CPD+CX ≥ 5 mm</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>100</td>
<td>98.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(15/15)</td>
<td>(71/72)</td>
</tr>
<tr>
<td>CX synergy test</td>
<td>CPD+CX vs CPD ≥ 5 mm and CPD+CA+CX vs CPD+CA ≥ 5mm</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>100</td>
<td>96.36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(32/32)</td>
<td>(53/55)</td>
</tr>
<tr>
<td>CA+CX synergy test</td>
<td>Both CPD+CA+CX vs CPD+CX ≥ 5 mm and CPD+CA+CX vs CPD+CA ≥ 5 mm</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>88.89</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(8/9)</td>
<td>(78/78)</td>
</tr>
</tbody>
</table>

CPD=cefodoxime (10 µg); CA= clavulanic acid (10 µg); CX=cloxacillin (500 µg)
Figure 1. The algorithm for confirmation of and differentiation between ESBL, AmpC, and coproduction of ESBL and AmpC in Enterobacteriaceae. CA = clavulanic acid (10 µg); CX = cloxacillin (500 µg).

156x67mm (300 x 300 DPI)
Figure 2. Phenotypic results from RCA plate assay with a combined disc method at 7 h. A = cefpodoxime (10 µg); B = cefpodoxime (10 µg) + clavulanic acid (10 µg); C = cefpodoxime (10 µg) + cloxacillin (500 µg); D = cefpodoxime (10 µg) + clavulanic acid (10 µg) + cloxacillin (500 µg); E = meropenem (10 µg).
Figure 3. Distribution of zone diameters of cefpodoxime (CPD) alone, CPD with clavulanic acid, CPD with cloxacillin, CPD with both clavulanic acid and cloxacillin and meropenem alone. A = ESBL producers (n=15); B = AmpC producers (n=32); C = co-producers AmpC and ESBL (n=9); D = carbapenemase producers (n=30). CPD=cefepodoxime (10 µg); CA= clavulanic acid (10 µg); CX=cloxacillin (500 µg); MER = meropenem (10 µg). ° = mild outlier; * extreme outlier.